Description
De-nol Tablets 120 mg. №112
Composition
De-nol tablets contain 120 mg of bismuth subcitrate.
Mechanism of Action
Bismuth subcitrate in De-nol tablets exerts its therapeutic effects by forming a protective layer over peptic ulcers, facilitating healing, and exhibiting anti-inflammatory properties. It also possesses anti-bacterial properties that aid in eradicating Helicobacter pylori infections.
Pharmacological Properties
De-nol tablets containing bismuth subcitrate demonstrate anti-ulcer, anti-inflammatory, and anti-bacterial activities, making them effective in the treatment of peptic ulcers and Helicobacter pylori infections.
Indications for Use
De-nol tablets are indicated for the treatment of peptic ulcers and Helicobacter pylori infections.
Contraindications
Avoid using De-nol tablets if you have a known allergy to bismuth subcitrate or any other components of the tablets.
Side Effects
Common side effects of De-nol tablets may include nausea, vomiting, diarrhea, and changes in taste perception. Consult your healthcare provider if you experience any adverse reactions.
Usage Instructions
The recommended dosage of De-nol tablets is 120 mg to be taken four times a day. Follow the instructions provided by your healthcare provider and do not exceed the prescribed dose.
Benefits Compared to Analogues
De-nol tablets have been shown to be as effective as standard triple therapy in eradicating Helicobacter pylori infections, with the added advantage of lower rates of antibiotic resistance.
Suitable Patient Groups
De-nol tablets are suitable for use in adults, including the elderly population, for the treatment of peptic ulcers and Helicobacter pylori infections. The use of De-nol in children should be determined by a healthcare professional.
Storage and Shelf Life
Store De-nol tablets in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use the tablets beyond the specified shelf life.
Packaging Description
De-nol tablets are available in a package containing 112 tablets of 120 mg strength each.
Clinical Evidence and Proven Effectiveness
In a comparative study published in the Journal of Gastroenterology, De-nol tablets demonstrated efficacy comparable to standard triple therapy in eradicating Helicobacter pylori infections. The study also highlighted the lower incidence of antibiotic resistance associated with De-nol treatment.
